Skip to main content
. 2021 Nov 1;27:e932275-1–e932275-15. doi: 10.12659/MSM.932275

Figure 5.

Figure 5

Assessment for chemotherapeutic responses to cisplatin and etoposide. (A) The estimated IC50 of cisplatin and etoposide to MCM-2. (B) The estimated IC50 of cisplatin and etoposide to EZH2. (C) The estimated IC50 of cisplatin and etoposide to CDKN2A. (D) The estimated IC50 of cisplatin and etoposide to CENPK. (E) The estimated IC50 of cisplatin and etoposide to CHEK1. (F) The estimated IC50 of cisplatin and etoposide to EXOSC2. (R software [Version 4.0.0, http://www.r-project.org]).